An FDA committee is recommending the addition of several peptides to the 503A bulk drug substances list.The FDA’s Pharmacy Compounding Advisory Committee, which has faced scrutiny for having several members with conflicts of interest, met July 23 and 24 to discuss peptides.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming…